E
HOWL icon

Ergoteles’s Werewolf Therapeutics HOWL Stock Holding History

Ergoteles’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,501
Closed -$54.3K – 1461
2022
Q4 		$54.3K Sell
26,501
-88,094
-77% -$230K ﹤0.01% 1283
2022
Q3 		$517K Sell
114,595
-14,405
-11% -$78.2K 0.02% 748
2022
Q2 		$528K Buy
+129,000
New +$589K 0.02% 813

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Ergoteles's HOWL Position: Q1 2023 in Review

Ergoteles sold out of Werewolf Therapeutics (HOWL) in Q1 2023, closing a stake of 26,501 shares — an estimated $54.3K sold.

Ergoteles first reported a position in HOWL in Q2 2022 and held it in 3 quarters. The position peaked at $528K in Q2 2022. 37 funds tracked by Wall St. Rank hold HOWL as of Q1 2023.

  • Ergoteles reported no remaining Werewolf Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 26,501 Werewolf Therapeutics shares in Q1 2023, an estimated $54.3K.
  • Ergoteles first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Werewolf Therapeutics position peaked at $528K in Q2 2022.
  • 37 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.